Skip to content
Biodatica
Start free

Silesian Centre for Heart Diseases

Opole, Opole Voivodeship

OncologyantibodyFiled/Approved
Compare Sign in to watch

What changed

Filed/Approved trial registered: Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Mar 2025Trial registeredMar 14, 2025Source filing (opens the source filing in a new tab)

Momentum

37no change

Momentum 37 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

56 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE4 registered

    Apr 17, 2024

    Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents, Sacubitril/Valsartan, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Molecular Mechanisms of Pharmacological Action, Heart Failure, Cardiac Toxicity, Cancer, Therapy-Related, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity · RECRUITING · sponsor: Silesian Centre for Heart Diseases · Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

    ClinicalTrials.gov · NCT05465031 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources